Lisdexamfetamine

Lisdexamfetamine

SCHEMBL31173641

C[C@H](Cc1ccccc1)NC(=O)[C@H](N)CCCCN

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC18A2SLC6A2SLC6A3

The experimentally established mechanism targets of Lisdexamfetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 2/20 0.64
▸ NPC1 O15118 2/20 0.55
▸ RAB9A P51151 2/20 0.55
▸ LTA4H P09960 1/20 0.52
▸ LMNA P02545 1/20 0.49
▸ TAAR1 Q96RJ0 1/20 0.48
▸ THRB P10828 1/20 0.47
▸ ANPEP P15144 1/20 0.47
▸ RNPEP Q9H4A4 1/20 0.47
▸ DNPEP Q9ULA0 1/20 0.47
▸ OPRK1 P41145 1/20 0.46
▸ CTSC P53634 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lisdexamfetamine SCHEMBL158949 1.00 MMP2 (0.64) MMP2NPC1RAB9ALTA4HLMNA
Lisdexamfetamine SCHEMBL7919487 1.00 MMP2 (0.64) MMP2NPC1RAB9ALTA4HLMNA
Lisdexamfetamine SCHEMBL25674417 1.00 MMP2 (0.64) MMP2NPC1RAB9ALTA4HLMNA
Lisdexamfetamine SCHEMBL31439237 1.00 MMP2 (0.64) MMP2NPC1RAB9ALTA4HLMNA
Lisdexamfetamine SCHEMBL12947679 1.00 MMP2 (0.64) MMP2NPC1RAB9ALTA4HLMNA
Lisdexamfetamine SCHEMBL579061 1.00 MMP2 (0.64) MMP2NPC1RAB9ALTA4HLMNA
SCHEMBL21657924 0.99 MMP2 (0.63) MMP2NPC1RAB9ALTA4HLMNA
SCHEMBL1844896 0.96 MMP2 (0.59) MMP2NPC1RAB9ALTA4HLMNA
Lisdexamfetamine SCHEMBL970534 0.95 MMP2 (0.59) MMP2NPC1RAB9ALTA4HLMNA
Lisdexamfetamine SCHEMBL678421 0.95 MMP2 (0.59) MMP2NPC1RAB9ALTA4HLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260060931-A1 METHOD FOR PREPARATION OF LISDEXAMFETAMINE DIMESYLATE DISPERSIBLE TABLET ATHENA PHARMACEUTIQUES SAS (FR) 2026-03-05 — — US disclosed
US-20250302774-A1 LISDEXAMFETAMINE DIMESYLATE ORODISPERSIBLE TABLET AND PROCESS FOR PREPARATION THEREOF ATHENA PHARMACEUTIQUES SAS (FR) 2025-10-02 — — US disclosed
CN-119000896-A Analysis and detection method for dextroamphetamine mesylate enantiomer and application thereof 宜昌人福药业有限责任公司 2024-11-22 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260060931-A1 METHOD FOR PREPARATION OF LISDEXAMFETAMINE DIMESYLATE DISPERSIBLE TABLET SORD, GMDS, GRN MMP2 1177/4885NPC1 2259/4885RAB9A 1709/4885
US-20250302774-A1 LISDEXAMFETAMINE DIMESYLATE ORODISPERSIBLE TABLET AND PROCESS FOR PREPARATION THEREOF SORD, NSF, SI MMP2 3343/4885NPC1 1726/4885RAB9A 1915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback